- Acquisition diversifies companys hematology, neurology and critical care commercial portfolio with addition of only approved Factor Xa inhibitor reversal agent - Alexion Pharmaceuticals, Inc. (ALXN) today announced the successful completion of its acquisition of Portola Pharmaceuticals, Inc. (PTLA). The acquisition adds Factor Xa inhibitor reversal agent Andexxa® [coagulation factor Xa, inactivated-zhzo],...
MANDEVILLE, La., July 1, 2020 With global biopharmaceutical companies racing to develop the first COVID-19 vaccine, Louisiana-based MECO ramps up production of water purification systems required in biopharmaceutical research and development. George Gsell, MECO President.
Avadel Pharmaceuticals (AVDL) plc , a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in patients with narcolepsy, today announced the sale of its portfolio of sterile injectable drugs used in the hospital setting, including three commercial products, Bloxiverz®, Vazculep®, and Akovaz®, as well ...
NEW YORK, June 30, 2020 Q BioMed Inc. (QBIO), a commercial stage biotech company, today issued a letter to shareholders. Dear Fellow Shareholders, We are extremely pleased to have reached our initial goal of becoming a commercial pharmaceutical company. We expect to book revenues in the current quarter, even as COVID restrictions have limited our access to hospitals and physicians.
Arya Sciences Acquisition Corp. (ARYA), a special purpose acquisition company sponsored by Perceptive Advisors, and Immatics Biotechnologies GmbH, a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting cancer immunotherapies, today announced that its respective shareholders approved the business combination between Arya and Immatics announced on March ...
RESEARCH TRIANGLE PARK, N.C., June 29, 2020 -- Liquidia Technologies, Inc. (LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT® technology, announced it has entered into a definitive agreement to acquire RareGen, LLC, a portfolio company of PBM Capital, through an all-stock merger.
WASHINGTON, June 26, 2020 HSRC announces the publication of its research report, "COVID-19 Pandemic Mitigation Products Market - 2020-2024". The COVID-19 pandemic has led to acute deficiencies of essential testing products, consumables and reagents from robotic PCRs and COVID-19 PCR reagents to swabs and COVID-19 serologic tests kits.
- "Growth of ALL market is expected to be driven by rising incident cases of ALL, steady uptake of approved and emerging therapies along with an expected increase in investment in the R&D activities.
KING OF PRUSSIA, Pa., June 24, 2020 Global biotherapeutics leader CSL Behring announced today that it has agreed to acquire exclusive global license rights to commercialize an adeno-associated virus gene therapy program, AMT-061, for the treatment of hemophilia B from uniQure, a leading gene therapy company. Paul Perreault.
News, commentary and research reports are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.
PDF’s require Adobe® Reader® and will open in a new window.
